Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Expert Review of Hematology

• Publication date

  2016-07-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/17474086.2016.1208082PMID 27355397
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Engraftment and outcomes following autologous stem cell transplantation in Hodgkin lymphoma patients mobilized with plerixafor

  2017cited by this paper
• Cost analysis of a randomized stem cell mobilization study in multiple myeloma

  2016cited by this paper
• Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually

  2016cited by this paper
• Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean multicenter retrospective study

  2016cited by this paper
• Early immune recovery after autologous transplantation in non-Hodgkin lymphoma patients: predictive factors and clinical significance

  2016cited by this paper
• Role of plerixafor in autologous stem cell mobilization with vinorelbine chemotherapy and granulocyte-colony stimulating factor in patients with myeloma: a phase II study (PAV-trial)

  2015cited by this paper
• Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma.

  2015cited by this paper
• Evaluating the use of plerixafor in stem cell mobilisation – an economic analysis of the PHANTASTIC trial

  2015cited by this paper
• Blood graft cellular composition and posttransplant recovery in non‐Hodgkin's lymphoma patients mobilized with or without plerixafor: a prospective comparison

  2015cited by this paper
• A nationwide survey of the use of plerixafor in patients with lymphoid malignancies who mobilize poorly demonstrates the predominant use of the “on‐demand” scheme of administration at French autologous hematopoietic stem cell transplant programs

  2015cited by this paper
• Plerixafor in combination with granulocyte–colony‐stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial

  2015cited by this paper
• Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients

  2014cited by this paper
• Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation.

  2014cited by this paper
• Engraftment and outcome after autologous stem cell transplantation in plerixafor‐mobilized non‐Hodgkin's lymphoma patients

  2014cited by this paper
• Unraveling stem cell and progenitor subsets in autologous grafts according to methods of mobilization: implications for prediction of hematopoietic recovery.

  2014cited by this paper
• Association between mobilization regimen and PFS after auto-SCT for multiple myeloma

  2014cited by this paper
• A plerixafor-based strategy allows adequate hematopoietic stem cell collection in poor mobilizers: results from the Canadian Special Access Program

  2014cited by this paper
• Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial

  2014cited by this paper
• Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma

  2014cited by this paper
• Plerixafor on‐demand combined with chemotherapy and granulocyte colony‐stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs

  2014cited by this paper
• Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation

  2014cited by this paper
• The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by “on-demand” addition of plerixafor to granulocyte–colony-stimulating factor

  2014cited by this paper
• Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial

  2013cited by this paper
• The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor

  2013cited by this paper
• Pharmacoeconomics of hematopoietic stem cell mobilization: an overview of current evidence and gaps in the literature.

  2013cited by this paper
• Phase 2 trial of Intravenously Administered Plerixafor for Stem Cell Mobilization in Patients with Multiple Myeloma Following Lenalidomide Based Initial Therapy

  2013cited by this paper
• The High-Affinity CXCR4 Antagonist BKT140 Is Safe and Induces a Robust Mobilization of Human CD34+ Cells in Patients with Multiple Myeloma

  2013cited by this paper
• Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin’s lymphoma and multiple myeloma: results from the expanded access program

  2013cited by this paper
• Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma

  2013cited by this paper
• Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells.

  2013cited by this paper
• Characterization of peripheral blood stem cell grafts mobilized by granulocyte colony-stimulating factor and plerixafor compared with granulocyte colony-stimulating factor alone.

  2013cited by this paper
• A specific time course for mobilization of peripheral blood CD34+ cells after plerixafor injection in very poor mobilizer patients: impact on the timing of the apheresis procedure

  2013cited by this paper
• CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients

  2013cited by this paper
• Sowing the Seeds of a Fruitful Harvest: Hematopoietic Stem Cell Mobilization

  2013cited by this paper
• Safety and efficacy of upfront plerixafor + G‐CSF versus placebo + G‐CSF for mobilization of CD34+ hematopoietic progenitor cells in patients ≥60 and <60 years of age with non‐Hodgkin's lymphoma or multiple myeloma

  2013cited by this paper
• Concise Review: Sowing the Seeds of a Fruitful Harvest: Hematopoietic Stem Cell Mobilization

  2013cited by this paper
• Kinetics of blood CD34+ cells after chemotherapy plus G-CSF in poor mobilizers: Implications for pre-emptive plerixafor use

  2012cited by this paper
• Preemptive use of plerixafor in difficult‐to‐mobilize patients: an emerging concept

  2012cited by this paper
• Predictive factors for poor peripheral blood stem cell mobilization and peak CD34(+) cell count to guide pre-emptive or immediate rescue mobilization.

  2012cited by this paper
• Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.

  2012cited by this paper
• Blood graft composition after plerixafor injection in patients with NHL

  2012cited by this paper
• Economic evaluation of plerixafor for stem cell mobilization.

  2012cited by this paper
• Pegfilgrastim‐ versus filgrastim‐based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis

  2012cited by this paper
• Blood graft lymphocyte subsets after plerixafor injection in non‐Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte–colony‐stimulating factor

  2012cited by this paper
• Pre-emptive plerixafor injection increases blood neutrophil, lymphocyte and monocyte counts in addition to CD34+ counts in patients with non-Hodgkin lymphoma mobilizing poorly with chemotherapy plus G-CSF: potential implications for apheresis and graft composition.

  2012cited by this paper
• European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization

  2012influential reference
• Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.

  2012cited by this paper
• Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma.

  2012cited by this paper
• Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization.

  2011cited by this paper
• Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens

  2011cited by this paper
• Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program

  2011cited by this paper
• Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide.

  2011cited by this paper
• Plerixafor

  2011cited by this paper
• Late afternoon dosing of plerixafor for stem cell mobilization: a practical solution.

  2011cited by this paper
• Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: a REL (Rete Ematologica Lombarda) experience.

  2011cited by this paper
• Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data

  2011cited by this paper
• Efficacy of pre‐emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience

  2011cited by this paper
• Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide

  2011cited by this paper
• Effectiveness and cost analysis of “just‐in‐time” salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics

  2011cited by this paper
• Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization

  2010cited by this paper
• Predicting Peripheral Blood Stem Cell Harvest Failure Using Circulating CD34 Levels: Developing Target-Based Cut-Points for Early Intervention

  2010cited by this paper
• Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation.

  2010cited by this paper
• Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)—Polish compassionate use experience

  2010cited by this paper
• review: Current status of stem cell mobilization

  2010cited by this paper
• Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation.

  2010cited by this paper
• Mobilization strategies in hard‐to‐mobilize patients with lymphoid malignancies

  2010cited by this paper
• Comparison of unmobilized and mobilized graft characteristics and the implications of cell subsets on autologous and allogeneic transplantation outcomes.

  2010cited by this paper
• Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization

  2010cited by this paper
• Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.

  2009cited by this paper
• Poor hematopoietic stem cell mobilizers: A single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma

  2009cited by this paper
• Improving stem cell mobilization strategies: future directions

  2009cited by this paper
• A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study.

  2009cited by this paper
• Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.

  2009influential reference
• The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil).

  2009cited by this paper
• Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.

  2009influential reference
• Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol.

  2009cited by this paper
• AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data

  2008cited by this paper
• Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.

  2008cited by this paper
• A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma.

  2008cited by this paper
• Improved Mobilization of Peripheral Blood CD34+ Cells and Dendritic Cells by AMD3100 plus Granulocyte–Colony-Stimulating Factor in Non-Hodgkin's Lymphoma Patients

  2007cited by this paper
• AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma.

  2007cited by this paper
• CD34(+) CD38(-) and CD34(+) HLA-DR(-) cells in BM stem cell grafts correlate with short-term engraftment but have no influence on long-term hematopoietic reconstitution after autologous transplantation.

  2006cited by this paper
• Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation

  2006cited by this paper
• The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone.

  2005influential reference
• Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist

  2005cited by this paper
• Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte–colony‐stimulating factor by single‐dose administration of AMD3100, a CXCR4 antagonist

  2005cited by this paper
• Leukocytosis and Mobilization of CD34+ Hematopoietic Progenitor Cells by AMD3100, a CXCR4 Antagonist.

  2004cited by this paper
• Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma.

  2004cited by this paper
• Poor Mobilization of Peripheral Blood Stem Cells is a Risk Factor for Worse Outcome in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation

  2003cited by this paper
• Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist.

  2003cited by this paper
• Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells.

  2000cited by this paper

• Impact of plerixafor use in the mobilization of blood grafts for autologous hematopoietic cell transplantation

  2024cites this paper
• Mobilization and Hematopoietic Stem Cell Collection in Poor Mobilizing Patients with Lymphoma: Final Results of the German OPTIMOB Study

  2023cites this paper
• Stem cell mobilizating effect of heparin in patients undergoing autologous stem cell transplantation

  2023cites this paper
• Mobilization Strategies in Myeloma Patients Intended for Autologous Hematopoietic Cell Transplantation

  2023cites this paper
• A vasculature-centric approach to developing novel treatment options for glioblastoma

  2021cites this paper
• A prospective comparison of pegfilgrastim and lipegfilgrastim combined with chemotherapy in the mobilization of CD34+ cells in NHL patients

  2020cites this paper
• Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Autologous Transplantation Seems Less Efficacious in Poor Mobilizers with the Use of a Biosimilar of Filgrastim and Plerixafor: A Retrospective Comparative Analysis

  2020cites this paper
• CMAR_A_219242 8371..8377

  2019cites this paper
• Efficacy and safety of plerixafor for hematopoietic stem cell mobilization for autologous transplantation in patients with non-Hodgkin lymphoma and multiple myeloma: A systematic review and meta-analysis

  2019influential citation
• rhTPO combined with chemotherapy and G-CSF for autologous peripheral blood stem cells in patients with refractory/relapsed non-Hodgkin’s lymphoma

  2019cites this paper
• Comparison of 10 and 20 µg/Kg/day PD-Grastim in Stem Cell Mobilization in Patients with Hematologic Malignancies Candidate for Autologous Stem Cell Transplantation

  2018cites this paper
• Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines

  2018cites this paper
• Impact of lenalidomide‐based induction therapy on the mobilization of CD34+ cells, blood graft cellular composition, and post‐transplant recovery in myeloma patients: a prospective multicenter study

  2017cites this paper
• Difficulties of Mobilization and Harvesting of Hematopoietic Stem Cells in Heavily Pre-Treated Patients

  2017cites this paper
• Preemptive plerixafor injection added to pegfilgrastim after chemotherapy in non-Hodgkin lymphoma patients mobilizing poorly

  2017cites this paper